Latest News and Press Releases

Boca Raton, FL, May 22, 2024 (GLOBE NEWSWIRE) -- The Cardiometabolic Health Congress (CMHC) is proud to announce that one of the foremost authorities in atherosclerosis, Peter Libby, MD, will...

To learn more about ZyVersa's Inflammasome ASC Inhibitor and Renal Pipelines, schedule a one-on-one meeting on 2024 BIO International Conference's Portal.

Inhibiting inflammasome pathways has potential to attenuate atherosclerosis in patients with diabetes, a leading cause of morbidity & mortality.

Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.

AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.

Pune, India, Aug. 11, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on “Endothelial Dysfunction Market Size Report & Share, Forecast to 2028 – COVID-19 Impact and...

New York, March 20, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Curcumin Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by...

MOUNTAIN VIEW, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Underdog Pharmaceuticals, a key investment of Michael Greve's rejuvenation biotech VC Kizoo, has closed a $10 million round of capital....

MOUNTAIN VIEW, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Underdog Pharmaceuticals, Inc. (Underdog), a pre-clinical stage pharmaceutical company focusing on the treatment and reversal of age-related...

Portland, OR, Feb. 15, 2021 (GLOBE NEWSWIRE) -- According to the report, the global inflation devices market was valued at $517 million in 2018, and is expected to reach $770 million by 2026,...